98%
921
2 minutes
20
Microorganisms play important roles in obesity; however, the role of the gut microbiomes in obesity is controversial because of the inconsistent findings. This study investigated the gut microbiome communities in obese and lean groups of captive healthy cynomolgus monkeys reared under strict identical environmental conditions, including their diet. No significant differences in the relative abundance of , and were observed between the obese and lean groups, but a significant difference in ( < 0.05) was noted. Microbial diversity and richness were similar, but highly variable results in microbial composition, diversity, and richness were observed in individuals, irrespective of their state of obesity. Distinct clustering between the groups was not observed by principal coordinate analysis using an unweighted pair group method. Higher sharedness values (95.81% ± 2.28% at the genus level, and 79.54% ± 5.88% at the species level) were identified among individual monkeys. This paper reports the association between the gut microbiome and obesity in captive non-human primate models reared under controlled environments. The relative proportion of and as well as the microbial diversity known to affect obesity were similar in the obese and lean groups of monkeys reared under identical conditions. Therefore, obesity-associated microbial changes reported previously appear to be associated directly with environmental factors, particularly diet, rather than obesity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538515 | PMC |
http://dx.doi.org/10.4142/jvs.2019.20.e19 | DOI Listing |
Ann Pediatr Endocrinol Metab
August 2025
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
Ever since its discovery, glucagon-like-peptide 1 (GLP-1) and drugs with similar function (collectively GLP-1s) have been used for type 2 diabetes mellitus and have been effective for obesity. Their profound effect on weight loss has resulted in widespread use of these medicines for treating obesity. Extensive studies have shown that GLP-1s decrease body weight, lean mass, and other metabolic phenotypes.
View Article and Find Full Text PDFDiabetes Metab Res Rev
September 2025
Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Bari, Italy.
Overweight and obesity represent common chronic metabolic disorders in the general population, and observed trends describe a substantial growth in the prevalence of weight excess also among individuals with type 1 diabetes (T1D), the so-called 'lean phenotype' of diabetes. The sharp rise of weight excess and obesity-related cardio-nephron-metabolic burdens observed in T2D is expected to produce similar consequences in T1D, leading to the urgent need to endorse therapeutic protocols as in most parts of the World no adjunctive treatments are approved for T1D, making weight excess management challenging in these individuals. The notable results shown by newer glucagon-like peptide 1 receptor agonists (GLP-1RAs) and emerging dual agonists, especially while managing cardio-metabolic burdens, in T2D have encouraged fervent anecdotal and non-anecdotal research also in T1D, indicating that non-insulin injective agents can be effective and safe.
View Article and Find Full Text PDFOsteoarthritis Cartilage
September 2025
Clinical Epidemiology Unit, Orthopaedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address:
Aim: To summarise key epidemiological and therapeutic research on osteoarthritis (OA) published between April 2024 and March 2025.
Methods: A narrative review was conducted using the MEDLINE database, focusing on English-language studies involving human participants published between April 1, 2024 and March 31, 2025. Eligible studies included observational longitudinal studies, systematic reviews, meta-analyses, and phase II-IV randomised controlled trials (RCTs) examining OA treatment and epidemiology.
Mol Metab
September 2025
Department of Medicine, Division of Endocrinology & Metabolism, University of California San Diego; La Jolla, California, USA. Electronic address:
Obesity is intricately linked to various metabolic diseases; however, some individuals maintain metabolic health despite being classified as obese. A critical factor underlying this paradox is the expansion of white adipose tissue (WAT), which can occur through two mechanisms: hypertrophy (the enlargement of existing fat cells) and hyperplasia (the formation of new fat cells from adipocyte precursor cells, or APCs). Hyperplasia is regarded as a healthier mode of WAT expansion, as it tends to reduce inflammation and protect against insulin resistance.
View Article and Find Full Text PDFBMJ Open Sport Exerc Med
September 2025
University of Glasgow School of Cardiovascular and Metabolic Health, Glasgow, Scotland, UK.
Background: The prevalence of obesity has tripled over the past 35 years. Although caloric restriction reduces body fat, lean tissue is also lost. Resistance exercise may mitigate these effects.
View Article and Find Full Text PDF